久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

美國Proteintech Group，Inc.
PROTEINTECH GROUP，INC.于2001年在美國芝加哥成立，是一家以開發、生產、銷售抗體/重組蛋白及相關產品為主要業務的生物技術公司。同年在中國成立全資子公司武漢三鷹生物技術有限公司，2006年在英國曼徹斯特成立歐洲分公司Proteintech Europe,LTD。
PROTEINTECH GROUP作為一家擁有獨立品牌的抗體公司，自公司成立以來，致力于開發針對所有人類蛋白的抗體—人類抗體組計劃，迄今已生產出針對10,000種不同人類蛋白的10,000余種抗體，涵蓋了生命科學的各個研究領域。產品被發表在各大學術期刊的論文頻繁引用，在國際學術界建立了獨具特色的品牌和牢固的地位，是本領域內近年出現的佼佼者。
PROTEINTECH GROUP 作為全球最大的抗體生產商之一，擁有一支銳意進取的技術研發團隊和成熟穩定的技術平臺，每周都有新產品推出，信息在網站上實時更新，檢測數據日益完善。并且在全球建立了市場銷售網絡，美國，歐洲，中國和日本都建有庫存，可以做到24小時現貨發售，快捷方便！
PROTEINTECH GROUP致力于向全球客戶提供高質量的抗體以及相關的制備抗體服務，逐步擴大產品種類和范圍，力爭成為生物技術領域最優秀的產品供應商和生命科學工作者可信賴的朋友。我們堅信：您的成功就是我們的成功！

The mission of Proteintech Group, Inc is to develop, manufacture a wide spectrum of antibodies against all human proteins known as Human Antibody Projects, thus providing the most effective tools for the identification and quantization of the vast number of known or unknown disease markers. Our philosophy is to be a part of the solution of the research community by providing scientists with every possible antibody they will need and at a reasonable cost. As all founders of the company are bench-side researchers, we have the deepest appreciation for the highest standard of perfection that all scientists hold for their projects, and therefore we hold our products to the same standard. As a part of this research community, we firmly committed to be a silent partner of every research laboratory and every research project.

Therefore it is the responsibility of Proteintech Group to offer researches with a variety of antibodies and related products at highest quality as possible so that the researchers can focus on their creativity, skill and effort as well as funding, without ever having to concern with the quality of reagents used. We also committed to provide them at lowest possible cost because we understand that every dollar of the research grant is the result of hard work of the researchers. Every dollar we saved is a dollar they have earned.

As the silent partner in your research career, you can count on us to solve your supply and technical needs on antibodies and antibody related products. We deeply understand that only if you succeed, we will succeed.

Our Promise:

Proteintech Group offers a variety of polyclonal and monoclonal antibodies for your research. Each antibody is thoroughly tested for its ability to perform immunoprecipitation, immunoblotting and immunohistochemistry so that you can be confident in using them. Understanding each antibody has its unique applications and features, we also provide our customers with complete technical support and detailed instructions for each application. To maximize your research flexibility, we promise following services.

For Investors:

The antibody and antibody-related products for research, biotech and clinical diagnostics constitute huge but unsaturated market in the world, and it is subject to a high growth trend. In the US, the National Institute of Health alone receives 17 billion dollars federal funding, among that, 1.7 billion, i.e. 10% is spent on antibody and related reagents. Many private pharmaceutical companies spent many fold more on antibodies and its related products. Another growing market is the proteomic project (project to identify, profile all human proteins and their function), especially in the post genomic project period. Antibodies are the only type of reagents today to solve most problems in the Human Proteomic Project. It is estimated that some 300,000 different anti-human protein antibodies will be needed while there are only 10,000 Antigen specificities are available.

The mission of the Proteintech Group is to design, develop, and market antibody and antibody-chips in the Bioresearch field. The antibody will fill current market that accounts for a minimum of $ 1.7 billion dollars in potential sales. Each product shall be priced to appeal to researchers that stresses lowest cost and convenient.

The procedure of production and marketing has been tested. Projections from studies have shown that with a 2 million dollar initial investment, the company would expect $24 million in sales in year three with a net profit of approximately $20 million. The company would expect to have $38 million in revenue by year five. The company would be self sustained in year one and will be able to break even between year one and two, purely based on antibody production and sales.

in next five years, the estimated market of products yielded from proteomic project would reach to 40 billion. The Proteintech Group is currently developing antibody chips (a collection of thousand antibodies arranged in arrays for quick identification and quantitation of known or unknown proteins in a mixture, such as in blood), a key product of this market. With its advantages of its massive antibody production, the proposed company would gain an edge in the production of antibody chips.